Phase II Study to Evaluate the Efficacy and Safety of Fruquintinib Plus Sintilimab as Third-line Therapy for Colorectal Cancer

NCT04179084 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

30

Enrollment

OTHER

Sponsor class

Conditions

Metastasis Colorectal Cancer

Interventions

DRUG: fruquintinib
DRUG: Sintilimab

Sponsor

Chinese PLA General Hospital